{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T11:59:31Z","timestamp":1784030371382,"version":"3.55.0"},"reference-count":37,"publisher":"Royal College of General Practitioners","issue":"745","license":[{"start":{"date-parts":[[2019,2,12]],"date-time":"2019-02-12T00:00:00Z","timestamp":1549929600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Gen Pract"],"accepted":{"date-parts":[[2023,11,20]]},"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>The cost-effectiveness of molnupiravir, an oral antiviral for early treatment of SARS-CoV-2, has not been established in vaccinated populations.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Aim<\/jats:title>\n<jats:p>To evaluate the cost-effectiveness of molnupiravir relative to usual care alone among mainly vaccinated community-based people at higher risk of severe outcomes from COVID-19 over 6 months.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Design and setting<\/jats:title>\n<jats:p>An economic evaluation of the PANORAMIC trial in the UK.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Method<\/jats:title>\n<jats:p>A cost-utility analysis that adopted a UK NHS and personal social services perspective and a 6-month time horizon was performed using PANORAMIC trial data. Cost-effectiveness was expressed in terms of incremental cost per quality-adjusted life year (QALY) gained. Sensitivity and subgroup analyses assessed the impacts of uncertainty and heterogeneity. Threshold analysis explored the price for molnupiravir consistent with likely reimbursement.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>In the base-case analysis, molnupiravir had higher mean costs of \u00a3449 (95% confidence interval [CI] = 445 to 453) and higher mean QALYs of 0.0055 (95% CI = 0.0044 to 0.0067) than usual care (mean incremental cost per QALY of \u00a381 190). Sensitivity and subgroup analyses showed similar results, except for those aged \u226575 years, with a 55% probability of being cost-effective at a \u00a330 000 per QALY threshold. Molnupiravir would have to be priced around \u00a3147 per course to be cost-effective at a \u00a315 000 per QALY threshold.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>At the current cost of \u00a3513 per course, molnupiravir is unlikely to be cost-effective relative to usual care over a 6-month time horizon among mainly vaccinated patients with COVID-19 at increased risk of adverse outcomes, except those aged \u226575 years.<\/jats:p>\n<\/jats:sec>","DOI":"10.3399\/bjgp.2023.0444","type":"journal-article","created":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T12:30:29Z","timestamp":1705408229000},"page":"e570-e579","source":"Crossref","is-referenced-by-count":9,"title":["Cost-utility analysis of molnupiravir for high-risk, community-based adults with COVID-19: an economic evaluation of the PANORAMIC trial"],"prefix":"10.3399","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5876-9363","authenticated-orcid":false,"given":"May Ee","family":"Png","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3345-2826","authenticated-orcid":false,"given":"Victoria","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7498-1276","authenticated-orcid":false,"given":"Jenna","family":"Grabey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8168-1746","authenticated-orcid":false,"given":"Nigel D","family":"Hart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7348-514X","authenticated-orcid":false,"given":"Bhautesh D","family":"Jani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8539-4181","authenticated-orcid":false,"given":"Daniel","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7580-7699","authenticated-orcid":false,"given":"Andrew","family":"Carson-Stevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Coates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0082-8468","authenticated-orcid":false,"given":"Lucy","family":"Cureton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4906-3956","authenticated-orcid":false,"given":"Melissa","family":"Dobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6072-1430","authenticated-orcid":false,"given":"Jienchi","family":"Dorward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5277-3545","authenticated-orcid":false,"given":"Philip","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8939-7312","authenticated-orcid":false,"given":"Nick","family":"Francis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2963-4491","authenticated-orcid":false,"given":"Oghenekome A","family":"Gbinigie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0852-627X","authenticated-orcid":false,"given":"Gail","family":"Hayward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7123-0004","authenticated-orcid":false,"given":"Jane","family":"Holmes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5268-8631","authenticated-orcid":false,"given":"Kerenza","family":"Hood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2769-0967","authenticated-orcid":false,"given":"Saye","family":"Khoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0634-8548","authenticated-orcid":false,"given":"Haroon","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8309-568X","authenticated-orcid":false,"given":"Mark","family":"Lown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micheal","family":"McKenna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6332-4641","authenticated-orcid":false,"given":"Sam","family":"Mort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2579-4655","authenticated-orcid":false,"given":"Jonathan S","family":"Nguyen-Van-Tam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1195-1680","authenticated-orcid":false,"given":"Najib M","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8093-7084","authenticated-orcid":false,"given":"Duncan B","family":"Richards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0460-6870","authenticated-orcid":false,"given":"Nicholas PB","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6229-5057","authenticated-orcid":false,"given":"Oliver","family":"van Hecke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7976-7172","authenticated-orcid":false,"given":"Richard","family":"Hobbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3664-1873","authenticated-orcid":false,"given":"Paul","family":"Little","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0331-7364","authenticated-orcid":false,"given":"Ly-Mee","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0102-3453","authenticated-orcid":false,"given":"Christopher C","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3121-6050","authenticated-orcid":false,"given":"Stavros","family":"Petrou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the PANORAMIC Trial Collaborators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1987","published-online":{"date-parts":[[2024,1,16]]},"reference":[{"key":"2024120415350976000_74.745.e570.1","unstructured":"Center for Systems Science and Engineering at Johns Hopkins University (2023) COVID-19 dashboard. https:\/\/www.arcgis.com\/apps\/dashboards\/bda7594740fd40299423467b48e9ecf6 (accessed 17 Jun 2024)."},{"key":"2024120415350976000_74.745.e570.2","unstructured":"World Health Organization (2022) 14.9 million excess deaths associated with the COVID-19 pandemic in 2020 and 2021. https:\/\/www.who.int\/news\/item\/05-05-2022-14.9-million-excess-deaths-were-associated-with-the-covid-19-pandemic-in-2020-and-2021 (accessed 17 Jun 2024)."},{"key":"2024120415350976000_74.745.e570.3","unstructured":"Office for Budget Responsibility (2021) International comparisons of the economic impact of the pandemic. https:\/\/obr.uk\/box\/international-comparisons-of-the-economic-impact-of-the-pandemic (accessed 17 Jun 2024)."},{"key":"2024120415350976000_74.745.e570.4","unstructured":"Office for National Statistics (2023) Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK: 30 March 2023. https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/healthandsocialcare\/conditionsanddiseases\/bulletins\/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk\/30march2023 (accessed 17 Jun 2024)."},{"key":"2024120415350976000_74.745.e570.5","doi-asserted-by":"publisher","DOI":"10.1126\/science.abj7364"},{"key":"2024120415350976000_74.745.e570.6","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2021.1957998"},{"key":"2024120415350976000_74.745.e570.7","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2100044"},{"issue":"4","key":"2024120415350976000_74.745.e570.8","doi-asserted-by":"crossref","first-page":"628","DOI":"10.3390\/v13040628","article-title":"Neutralizing antibody therapeutics for COVID-19","volume":"13","author":"Hurt","year":"2021","journal-title":"Viruses"},{"issue":"21","key":"2024120415350976000_74.745.e570.9","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMoa2107934","article-title":"Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab","volume":"385","author":"Gupta","year":"2021","journal-title":"N Engl J Med"},{"key":"2024120415350976000_74.745.e570.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA2116044\/SUPPL_FILE\/NEJMOA2116044_DATA-SHARING.PDF"},{"key":"2024120415350976000_74.745.e570.11","unstructured":"Medicines and Healthcare products Regulatory Agency (2021) First oral antiviral for COVID-19, Lagevrio (molnupiravir), approved by MHRA. https:\/\/www.gov.uk\/government\/news\/first-oral-antiviral-for-covid-19-lagevrio-molnupiravir-approved-by-mhra (accessed 17 Jun 2024)."},{"key":"2024120415350976000_74.745.e570.12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02597-1"},{"issue":"1","key":"2024120415350976000_74.745.e570.13","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jval.2021.10.008","article-title":"Consolidated health economic evaluation reporting standards (CHEERS) 2022 explanation and elaboration: a report of the ISPOR CHEERS II Good Practices Task Force","volume":"25","author":"Husereau","year":"2022","journal-title":"Value Health"},{"key":"2024120415350976000_74.745.e570.14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01744-X"},{"key":"2024120415350976000_74.745.e570.15","doi-asserted-by":"publisher","DOI":"10.1177\/1077558705285298"},{"key":"2024120415350976000_74.745.e570.16","unstructured":"Jones K Burns A (2022) Unit costs of health and social care 2021. https:\/\/www.pssru.ac.uk\/project-pages\/unit-costs\/unit-costs-of-health-and-social-care-2021 (accessed 17 Jun 2024)."},{"key":"2024120415350976000_74.745.e570.17","unstructured":"Reed J (Nov 4, 2021) Molnupiravir: first pill to treat Covid gets approval in UK. BBC News, https:\/\/www.bbc.co.uk\/news\/health-59163899 (accessed 17 Jun 2024)."},{"key":"2024120415350976000_74.745.e570.18","unstructured":"NHS England (2023) National cost collection for the NHS. https:\/\/www.england.nhs.uk\/national-cost-collection (accessed 17 Jun 2024)."},{"key":"2024120415350976000_74.745.e570.19","unstructured":"NHS Business Services Authority (2021) Prescription cost analysis (PCA) data. https:\/\/www.nhsbsa.nhs.uk\/prescription-data\/dispensing-data\/prescription-cost-analysis-pca-data (accessed 17 Jun 2024)."},{"key":"2024120415350976000_74.745.e570.20","unstructured":"Office for National Statistics (2022) Employee earnings in the UK: 2022. https:\/\/www.ons.gov.uk\/employmentandlabourmarket\/peopleinwork\/earningsandworkinghours\/bulletins\/annualsurveyofhoursandearnings\/2022 (accessed 17 Jun 2024)."},{"key":"2024120415350976000_74.745.e570.21","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-011-9903-x"},{"key":"2024120415350976000_74.745.e570.22","unstructured":"National Institute for Health and Care Excellence (2023) NICE health technology evaluations: the manual. PMG36 (NICE, London) https:\/\/www.nice.org.uk\/process\/pmg36\/chapter\/introduction-to-health-technology-evaluation (accessed 17 Jun 2024)."},{"key":"2024120415350976000_74.745.e570.23","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-022-01218-7"},{"key":"2024120415350976000_74.745.e570.24","doi-asserted-by":"crossref","unstructured":"Drummond MF Sculpher MJ Torrance GW (2005) Methods for the economic evaluation of health care programmes (Oxford University Press, Oxfrod), 3rd edn.","DOI":"10.1093\/oso\/9780198529446.001.0001"},{"key":"2024120415350976000_74.745.e570.25","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-014-0193-3"},{"key":"2024120415350976000_74.745.e570.26","doi-asserted-by":"crossref","unstructured":"Rubin D (1987) Multiple imputation for nonresponse in surveys (John Wiley & Sons, New York, NY).","DOI":"10.1002\/9780470316696"},{"key":"2024120415350976000_74.745.e570.27","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v045.i05"},{"key":"2024120415350976000_74.745.e570.28","doi-asserted-by":"publisher","DOI":"10.2196\/jmir.1448"},{"key":"2024120415350976000_74.745.e570.29","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4067"},{"key":"2024120415350976000_74.745.e570.30","unstructured":"National Institute for Health and Care Excellence (2013) Judging whether public health interventions offer value for money LGB10 (NICE, London) https:\/\/www.nice.org.uk\/advice\/lgb10\/chapter\/judging-the-cost-effectiveness-of-public-health-activitiesMethodsfortheeconomicevaluationofhealthcareprogrammes (accessed 17 Jun 2024)."},{"key":"2024120415350976000_74.745.e570.31","doi-asserted-by":"publisher","DOI":"10.3310\/hta19880"},{"key":"2024120415350976000_74.745.e570.32","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-069176"},{"key":"2024120415350976000_74.745.e570.33","unstructured":"Australian Government Department of Health and Aged Care (2022) Use of Lagevrio (molnupiravir) in residential aged care, https:\/\/www.health.gov.au\/sites\/default\/files\/documents\/2022\/07\/coronavirus-covid-19-use-of-lagevrio-molnupiravir-in-residential-aged-care.pdf (accessed 17 Jun 2024)."},{"key":"2024120415350976000_74.745.e570.34","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-022-01168-0"},{"key":"2024120415350976000_74.745.e570.35","doi-asserted-by":"publisher","DOI":"10.4178\/epih.e2022034"},{"key":"2024120415350976000_74.745.e570.36","first-page":"100602","article-title":"Association of molnupiravir and nirmatrelvir-ritonavir with preventable mortality, hospital admissions and related avoidable healthcare system cost among high-risk patients with mild to moderate COVID-19","volume":"30","author":"Wai","year":"2023","journal-title":"Lancet Reg Health West Pac"},{"key":"2024120415350976000_74.745.e570.37","unstructured":"Exchange Rates UK (2024) US dollar to British pound spot exchange rates for 2022. https:\/\/www.exchangerates.org.uk\/USD-GBP-spot-exchange-rates-history-2022.html (accessed 17 Jun 2024)."}],"container-title":["British Journal of General Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3399\/BJGP.2023.0444","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T04:16:21Z","timestamp":1733372181000},"score":1,"resource":{"primary":{"URL":"http:\/\/bjgp.org\/lookup\/doi\/10.3399\/BJGP.2023.0444"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,16]]},"references-count":37,"journal-issue":{"issue":"745","published-online":{"date-parts":[[2024,7,25]]},"published-print":{"date-parts":[[2024,8]]}},"alternative-id":["10.3399\/BJGP.2023.0444"],"URL":"https:\/\/doi.org\/10.3399\/bjgp.2023.0444","relation":{},"ISSN":["0960-1643","1478-5242"],"issn-type":[{"value":"0960-1643","type":"print"},{"value":"1478-5242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,16]]}}}